이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Secondary Prevention of Venous Thrombo Embolism (VTE). (RE-MEDY)

2014년 5월 8일 업데이트: Boehringer Ingelheim

A Phase III, Randomised, Multicenter, Double-blind, Parallel-group, Active Controlled Study to Evaluate the Efficacy and Safety of Oral Dabigatran Etexilate (150 mg Bid) Compared to Warfarin (INR 2.0-3.0) for the Secondary Prevention of Venous Thromboembolism.

The general aim of this study is to determine the comparative safety and efficacy of dabigatran etexilate administered orally and warfarin (International Normalized Ratio (INR) of 2.0-3.0) for the long-term treatment and secondary prevention of symptomatic venous thromboembolism in patients who have been successfully treated with standard doses of an approved anticoagulant for three to twelve months for confirmed acute symptomatic Venous Thrombo-embolism.

연구 개요

상태

완전한

연구 유형

중재적

등록 (실제)

2867

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스
        • 1160.47.30001 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.47.30006 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.47.30007 Boehringer Ingelheim Investigational Site
      • Athens, 그리스
        • 1160.47.30009 Boehringer Ingelheim Investigational Site
      • Johannesburg, 남아프리카
        • 1160.47.27001 Boehringer Ingelheim Investigational Site
      • Johannesburg, 남아프리카
        • 1160.47.27002 Boehringer Ingelheim Investigational Site
      • Johannesburg, 남아프리카
        • 1160.47.27006 Boehringer Ingelheim Investigational Site
      • Pretoria, 남아프리카
        • 1160.47.27007
      • Randburg, 남아프리카
        • 1160.47.27003 Boehringer Ingelheim Investigational Site
      • Roodepoort, 남아프리카
        • 1160.47.27005 Boehringer Ingelheim Investigational Site
      • Amersfoort, 네덜란드
        • 1160.47.31001 Boehringer Ingelheim Investigational Site
      • Amsterdam, 네덜란드
        • 1160.47.31006 Boehringer Ingelheim Investigational Site
      • Amsterdam, 네덜란드
        • 1160.47.31007 Boehringer Ingelheim Investigational Site
      • Den Bosch, 네덜란드
        • 1160.47.31010 Boehringer Ingelheim Investigational Site
      • Heerlen, 네덜란드
        • 1160.47.31014 Boehringer Ingelheim Investigational Site
      • Maastricht, 네덜란드
        • 1160.47.31005 Boehringer Ingelheim Investigational Site
      • Rotterdam, 네덜란드
        • 1160.47.31004 Boehringer Ingelheim Investigational Site
      • Rotterdam, 네덜란드
        • 1160.47.31009 Boehringer Ingelheim Investigational Site
      • Oslo, 노르웨이
        • 1160.47.47001 Boehringer Ingelheim Investigational Site
      • Oslo, 노르웨이
        • 1160.47.47004 Boehringer Ingelheim Investigational Site
      • Rud, 노르웨이
        • 1160.47.47003 Boehringer Ingelheim Investigational Site
      • Trondheim, 노르웨이
        • 1160.47.47005 Boehringer Ingelheim Investigational Site
      • Christchurch, 뉴질랜드
        • 1160.47.64004 Boehringer Ingelheim Investigational Site
      • Grafton, 뉴질랜드
        • 1160.47.64003 Boehringer Ingelheim Investigational Site
      • Otahuhu, 뉴질랜드
        • 1160.47.64002 Boehringer Ingelheim Investigational Site
      • Takapuna Auckland 9, 뉴질랜드
        • 1160.47.64001 Boehringer Ingelheim Investigational Site
      • Esbjerg, 덴마크
        • 1160.47.45008 Boehringer Ingelheim Investigational Site
      • Holbæk, 덴마크
        • 1160.47.45009 Boehringer Ingelheim Investigational Site
      • Kolding, 덴마크
        • 1160.47.45002 Boehringer Ingelheim Investigational Site
      • København NV, 덴마크
        • 1160.47.45004 Boehringer Ingelheim Investigational Site
      • København S, 덴마크
        • 1160.47.45007 Boehringer Ingelheim Investigational Site
      • Slagelse, 덴마크
        • 1160.47.45006 Boehringer Ingelheim Investigational Site
      • Dresden, 독일
        • 1160.47.49017 Boehringer Ingelheim Investigational Site
      • Dresden, 독일
        • 1160.47.49018 Boehringer Ingelheim Investigational Site
      • Köln, 독일
        • 1160.47.49003 Boehringer Ingelheim Investigational Site
      • Mannheim, 독일
        • 1160.47.49005 Boehringer Ingelheim Investigational Site
      • Mannheim, 독일
        • 1160.47.49006 Boehringer Ingelheim Investigational Site
      • München, 독일
        • 1160.47.49007 Boehringer Ingelheim Investigational Site
      • München, 독일
        • 1160.47.49008 Boehringer Ingelheim Investigational Site
      • Püttlingen, 독일
        • 1160.47.49009 Boehringer Ingelheim Investigational Site
      • Belgorod, 러시아 연방
        • 1160.47.07022 Boehringer Ingelheim Investigational Site
      • Chelyabinsk, 러시아 연방
        • 1160.47.07011 Boehringer Ingelheim Investigational Site
      • Chelyabinsk, 러시아 연방
        • 1160.47.07021 Boehringer Ingelheim Investigational Site
      • Ekaterinburg, 러시아 연방
        • 1160.47.07007 Boehringer Ingelheim Investigational Site
      • Krasnodar, 러시아 연방
        • 1160.47.07016 Boehringer Ingelheim Investigational Site
      • Kursk, 러시아 연방
        • 1160.47.07004 Boehringer Ingelheim Investigational Site
      • Novosibirsk, 러시아 연방
        • 1160.47.07010 Boehringer Ingelheim Investigational Site
      • Omsk, 러시아 연방
        • 1160.47.07020 Boehringer Ingelheim Investigational Site
      • Pskov, 러시아 연방
        • 1160.47.07018 Boehringer Ingelheim Investigational Site
      • Rostov-na-Donu, 러시아 연방
        • 1160.47.07009 Boehringer Ingelheim Investigational Site
      • Rostov-na-Donu, 러시아 연방
        • 1160.47.07023 Boehringer Ingelheim Investigational Site
      • Rostov-na-Donu, 러시아 연방
        • 1160.47.07024 Boehringer Ingelheim Investigational Site
      • Rostov-na-Donu, 러시아 연방
        • 1160.47.07025 Boehringer Ingelheim Investigational Site
      • St. Petersburg, 러시아 연방
        • 1160.47.07001 Boehringer Ingelheim Investigational Site
      • St. Petersburg, 러시아 연방
        • 1160.47.07002 Boehringer Ingelheim Investigational Site
      • St. Petersburg, 러시아 연방
        • 1160.47.07017 Boehringer Ingelheim Investigational Site
      • Tyumen, 러시아 연방
        • 1160.47.07019 Boehringer Ingelheim Investigational Site
      • Ufa, 러시아 연방
        • 1160.47.07014 Boehringer Ingelheim Investigational Site
      • Yaroslavl, 러시아 연방
        • 1160.47.07005 Boehringer Ingelheim Investigational Site
      • Yaroslavl, 러시아 연방
        • 1160.47.07006 Boehringer Ingelheim Investigational Site
      • Chihuahua, 멕시코
        • 1160.47.52036 Boehringer Ingelheim Investigational Site
      • Culiacan, 멕시코
        • 1160.47.52039 Boehringer Ingelheim Investigational Site
      • Guadalajara, Jal., 멕시코
        • 1160.47.52030 Boehringer Ingelheim Investigational Site
      • Monterrey, 멕시코
        • 1160.47.52027 Boehringer Ingelheim Investigational Site
      • San Luis Potosí, 멕시코
        • 1160.47.52034 Boehringer Ingelheim Investigational Site
    • Alabama
      • Mobile, Alabama, 미국
        • 1160.47.01035 Boehringer Ingelheim Investigational Site
    • Connecticut
      • Hartford, Connecticut, 미국
        • 1160.47.01056 Boehringer Ingelheim Investigational Site
    • Florida
      • Clearwater, Florida, 미국
        • 1160.47.01044 Boehringer Ingelheim Investigational Site
    • Georgia
      • Augusta, Georgia, 미국
        • 1160.47.01019 Boehringer Ingelheim Investigational Site
      • Decatur, Georgia, 미국
        • 1160.47.01008 Boehringer Ingelheim Investigational Site
    • Maryland
      • Baltimore, Maryland, 미국
        • 1160.47.01014 Boehringer Ingelheim Investigational Site
    • Massachusetts
      • Roxbury Crossing, Massachusetts, 미국
        • 1160.47.01018 Boehringer Ingelheim Investigational Site
    • Michigan
      • Detroit, Michigan, 미국
        • 1160.47.01023 Boehringer Ingelheim Investigational Site
    • Minnesota
      • St. Louis Park, Minnesota, 미국
        • 1160.47.01009 Boehringer Ingelheim Investigational Site
    • New Hampshire
      • Lebanon, New Hampshire, 미국
        • 1160.47.01031 Boehringer Ingelheim Investigational Site
    • New Mexico
      • Albuquerque, New Mexico, 미국
        • 1160.47.01036 Boehringer Ingelheim Investigational Site
    • North Carolina
      • Chapel Hill, North Carolina, 미국
        • 1160.47.01027 Boehringer Ingelheim Investigational Site
      • Winston-Salem, North Carolina, 미국
        • 1160.47.01039 Boehringer Ingelheim Investigational Site
    • North Dakota
      • Grand Forks, North Dakota, 미국
        • 1160.47.01030 Boehringer Ingelheim Investigational Site
    • Ohio
      • Toledo, Ohio, 미국
        • 1160.47.01013 Boehringer Ingelheim Investigational Site
    • Pennsylvania
      • Altoona, Pennsylvania, 미국
        • 1160.47.01052 Boehringer Ingelheim Investigational Site
    • South Carolina
      • Summerville, South Carolina, 미국
        • 1160.47.01055 Boehringer Ingelheim Investigational Site
    • Virginia
      • Richmond, Virginia, 미국
        • 1160.47.01017 Boehringer Ingelheim Investigational Site
      • Bruxelles, 벨기에
        • 1160.47.32001 Boehringer Ingelheim Investigational Site
      • Bruxelles, 벨기에
        • 1160.47.32002 Boehringer Ingelheim Investigational Site
      • Leuven, 벨기에
        • 1160.47.32005 Boehringer Ingelheim Investigational Site
      • Liège, 벨기에
        • 1160.47.32004 Boehringer Ingelheim Investigational Site
      • Plovdiv, 불가리아
        • 1160.47.35910 Boehringer Ingelheim Investigational Site
      • Rousse, 불가리아
        • 1160.47.35908 Boehringer Ingelheim Investigational Site
      • Sofia, 불가리아
        • 1160.47.35901 Boehringer Ingelheim Investigational Site
      • Sofia, 불가리아
        • 1160.47.35903 Boehringer Ingelheim Investigational Site
      • Sofia, 불가리아
        • 1160.47.35904 Boehringer Ingelheim Investigational Site
      • Sofia, 불가리아
        • 1160.47.35906 Boehringer Ingelheim Investigational Site
      • Sofia, 불가리아
        • 1160.47.35907 Boehringer Ingelheim Investigational Site
      • Varna, 불가리아
        • 1160.47.35905 Boehringer Ingelheim Investigational Site
      • Brasília, 브라질
        • 1160.47.55010 Boehringer Ingelheim Investigational Site
      • Campinas - SP, 브라질
        • 1160.47.55007 Boehringer Ingelheim Investigational Site
      • Curitiba, 브라질
        • 1160.47.55014 Boehringer Ingelheim Investigational Site
      • Juvene - Paraná -, 브라질
        • 1160.47.55017 Boehringer Ingelheim Investigational Site
      • Rio de Janeiro - RJ, 브라질
        • 1160.47.55016 Boehringer Ingelheim Investigational Site
      • São Bernardo do Campo, 브라질
        • 1160.47.55018 Boehringer Ingelheim Investigational Site
      • São José do Rio Preto, 브라질
        • 1160.47.55005 Boehringer Ingelheim Investigational Site
      • pTO aLEGRE, 브라질
        • 1160.47.55012 Boehringer Ingelheim Investigational Site
      • Göteborg, 스웨덴
        • 1160.47.46002 Boehringer Ingelheim Investigational Site
      • Jönköping, 스웨덴
        • 1160.47.46006 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.47.46001 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.47.46007 Boehringer Ingelheim Investigational Site
      • Stockholm, 스웨덴
        • 1160.47.46008 Boehringer Ingelheim Investigational Site
      • Sundsvall, 스웨덴
        • 1160.47.46005 Boehringer Ingelheim Investigational Site
      • Uppsala, 스웨덴
        • 1160.47.46003 Boehringer Ingelheim Investigational Site
      • Alicante, 스페인
        • 1160.47.34006 Boehringer Ingelheim Investigational Site
      • Badalona (Barcelona), 스페인
        • 1160.47.34012 Boehringer Ingelheim Investigational Site
      • Barcelona, 스페인
        • 1160.47.34001 Boehringer Ingelheim Investigational Site
      • Barcelona, 스페인
        • 1160.47.34002 Boehringer Ingelheim Investigational Site
      • Cartagena. Murcia, 스페인
        • 1160.47.34007 Boehringer Ingelheim Investigational Site
      • Cuenca, 스페인
        • 1160.47.34003 Boehringer Ingelheim Investigational Site
      • Madrid, 스페인
        • 1160.47.34009 Boehringer Ingelheim Investigational Site
      • Santander, 스페인
        • 1160.47.34004 Boehringer Ingelheim Investigational Site
      • Valencia, 스페인
        • 1160.47.34011 Boehringer Ingelheim Investigational Site
      • Banska Bystrica, 슬로바키아
        • 1160.47.42107 Boehringer Ingelheim Investigational Site
      • Lucenec, 슬로바키아
        • 1160.47.42106 Boehringer Ingelheim Investigational Site
      • Nitra, 슬로바키아
        • 1160.47.42102 Boehringer Ingelheim Investigational Site
      • Nove Zamky, 슬로바키아
        • 1160.47.42103 Boehringer Ingelheim Investigational Site
      • Zilina, 슬로바키아
        • 1160.47.42104 Boehringer Ingelheim Investigational Site
      • Adrogué, 아르헨티나
        • 1160.47.54017 Boehringer Ingelheim Investigational Site
      • Bahía Blanca, 아르헨티나
        • 1160.47.54015 Boehringer Ingelheim Investigational Site
      • Capital Federal, 아르헨티나
        • 1160.47.54001 Boehringer Ingelheim Investigational Site
      • Capital Federal, 아르헨티나
        • 1160.47.54003 Boehringer Ingelheim Investigational Site
      • Capital Federal, 아르헨티나
        • 1160.47.54005 Boehringer Ingelheim Investigational Site
      • Capital Federal, 아르헨티나
        • 1160.47.54006 Boehringer Ingelheim Investigational Site
      • Capital Federal, 아르헨티나
        • 1160.47.54007 Boehringer Ingelheim Investigational Site
      • Capital Federal, 아르헨티나
        • 1160.47.54010 Boehringer Ingelheim Investigational Site
      • La Plata, 아르헨티나
        • 1160.47.54016 Boehringer Ingelheim Investigational Site
      • Mar del Plata, 아르헨티나
        • 1160.47.54014 Boehringer Ingelheim Investigational Site
      • Quilmes, 아르헨티나
        • 1160.47.54013 Boehringer Ingelheim Investigational Site
      • Rosario, 아르헨티나
        • 1160.47.54011 Boehringer Ingelheim Investigational Site
      • Salta, 아르헨티나
        • 1160.47.54018 Boehringer Ingelheim Investigational Site
      • Santa Fe, 아르헨티나
        • 1160.47.54012 Boehringer Ingelheim Investigational Site
      • Headington, Oxford, 영국
        • 1160.47.44005 Boehringer Ingelheim Investigational Site
      • London, 영국
        • 1160.47.44009 Boehringer Ingelheim Investigational Site
      • London, 영국
        • 1160.47.44011 Boehringer Ingelheim Investigational Site
      • Newcastle upon Tyne, 영국
        • 1160.47.44006 Boehringer Ingelheim Investigational Site
      • Sheffield, 영국
        • 1160.47.44012 Boehringer Ingelheim Investigational Site
      • Graz, 오스트리아
        • 1160.47.43001 Boehringer Ingelheim Investigational Site
      • Innsbruck, 오스트리아
        • 1160.47.43003 Boehringer Ingelheim Investigational Site
      • Wien, 오스트리아
        • 1160.47.43002 Boehringer Ingelheim Investigational Site
      • Wien, 오스트리아
        • 1160.47.43004 Boehringer Ingelheim Investigational Site
      • Kharkov, 우크라이나
        • 1160.47.38002 Boehringer Ingelheim Investigational Site
      • Kiev, 우크라이나
        • 1160.47.38006 Boehringer Ingelheim Investigational Site
      • Vinnitsa, 우크라이나
        • 1160.47.38005 Boehringer Ingelheim Investigational Site
      • Zaporozhye, 우크라이나
        • 1160.47.38003 Boehringer Ingelheim Investigational Site
      • Afula, 이스라엘
        • 1160.47.97202 Boehringer Ingelheim Investigational Site
      • Ashkelon, 이스라엘
        • 1160.47.97207 Boehringer Ingelheim Investigational Site
      • Haifa, 이스라엘
        • 1160.47.97211 Boehringer Ingelheim Investigational Site
      • Holon, 이스라엘
        • 1160.47.97203 Boehringer Ingelheim Investigational Site
      • Kfar Saba, 이스라엘
        • 1160.47.97205 Boehringer Ingelheim Investigational Site
      • Petach Tikva, 이스라엘
        • 1160.47.97206 Boehringer Ingelheim Investigational Site
      • Rehovot, 이스라엘
        • 1160.47.97208 Boehringer Ingelheim Investigational Site
      • Tel Aviv, 이스라엘
        • 1160.47.97210 Boehringer Ingelheim Investigational Site
      • Tel Hashomer, 이스라엘
        • 1160.47.97204 Boehringer Ingelheim Investigational Site
      • Zerifin, 이스라엘
        • 1160.47.97201 Boehringer Ingelheim Investigational Site
      • Bologna, 이탈리아
        • 1160.47.39003 Boehringer Ingelheim Investigational Site
      • Cremona, 이탈리아
        • 1160.47.39004 Boehringer Ingelheim Investigational Site
      • Genova, 이탈리아
        • 1160.47.39006 Boehringer Ingelheim Investigational Site
      • Milano, 이탈리아
        • 1160.47.39008 Boehringer Ingelheim Investigational Site
      • Reggio Emilia, 이탈리아
        • 1160.47.39007 Boehringer Ingelheim Investigational Site
      • Udine, 이탈리아
        • 1160.47.39009 Boehringer Ingelheim Investigational Site
      • Vittorio Veneto, 이탈리아
        • 1160.47.39005 Boehringer Ingelheim Investigational Site
      • Ahmedabad, 인도
        • 1160.47.91002 Boehringer Ingelheim Investigational Site
      • Bangalore, 인도
        • 1160.47.91011 Boehringer Ingelheim Investigational Site
      • Bangalore, 인도
        • 1160.47.91015 Boehringer Ingelheim Investigational Site
      • Chennai, 인도
        • 1160.47.91012 Boehringer Ingelheim Investigational Site
      • Chennai, 인도
        • 1160.47.91017 Boehringer Ingelheim Investigational Site
      • Madurai, 인도
        • 1160.47.91009 Boehringer Ingelheim Investigational Site
      • Mysore, 인도
        • 1160.47.91007 Boehringer Ingelheim Investigational Site
      • New Delhi, 인도
        • 1160.47.91003 Boehringer Ingelheim Investigational Site
      • New Delhi, 인도
        • 1160.47.91010 Boehringer Ingelheim Investigational Site
      • Pune, 인도
        • 1160.47.91001 Boehringer Ingelheim Investigational Site
      • Pune, 인도
        • 1160.47.91005 Boehringer Ingelheim Investigational Site
      • Pune, 인도
        • 1160.47.91008 Boehringer Ingelheim Investigational Site
      • Trivandrum, 인도
        • 1160.47.91014 Boehringer Ingelheim Investigational Site
      • Vadodara, 인도
        • 1160.47.91004 Boehringer Ingelheim Investigational Site
      • new Delhi, 인도
        • 1160.47.91006 Boehringer Ingelheim Investigational Site
      • Beijing, 중국
        • 1160.47.86001 Boehringer Ingelheim Investigational Site
      • Beijing, 중국
        • 1160.47.86015 Boehringer Ingelheim Investigational Site
      • Chengdu, 중국
        • 1160.47.86014 Boehringer Ingelheim Investigational Site
      • Guangzhou, 중국
        • 1160.47.86012 Boehringer Ingelheim Investigational Site
      • Hangzhou, 중국
        • 1160.47.86009 Boehringer Ingelheim Investigational Site
      • Hangzhou, 중국
        • 1160.47.86010 Boehringer Ingelheim Investigational Site
      • Nanjing, 중국
        • 1160.47.86013 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86002 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86003 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86004 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86005 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86006 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86007 Boehringer Ingelheim Investigational Site
      • Shanghai, 중국
        • 1160.47.86016 Boehringer Ingelheim Investigational Site
      • Shijiazhuang, 중국
        • 1160.47.86011 Boehringer Ingelheim Investigational Site
      • Brno, 체코 공화국
        • 1160.47.42001 Boehringer Ingelheim Investigational Site
      • Hradec Kralove, 체코 공화국
        • 1160.47.42002 Boehringer Ingelheim Investigational Site
      • Hranice, 체코 공화국
        • 1160.47.42011 Boehringer Ingelheim Investigational Site
      • Liberec, 체코 공화국
        • 1160.47.42012 Boehringer Ingelheim Investigational Site
      • Novy Jicin, 체코 공화국
        • 1160.47.42015 Boehringer Ingelheim Investigational Site
      • Ostrava-Vitkovice, 체코 공화국
        • 1160.47.42005 Boehringer Ingelheim Investigational Site
      • Praha 2, 체코 공화국
        • 1160.47.42004 Boehringer Ingelheim Investigational Site
      • Tabor, 체코 공화국
        • 1160.47.42014 Boehringer Ingelheim Investigational Site
      • Usti nad Labem, 체코 공화국
        • 1160.47.42010 Boehringer Ingelheim Investigational Site
      • Zlin, 체코 공화국
        • 1160.47.42007 Boehringer Ingelheim Investigational Site
      • Ankara, 칠면조
        • 1160.47.90003 Boehringer Ingelheim Investigational Site
      • Ankara, 칠면조
        • 1160.47.90004 Boehringer Ingelheim Investigational Site
      • Ankara, 칠면조
        • 1160.47.90005 Boehringer Ingelheim Investigational Site
      • Istanbul, 칠면조
        • 1160.47.90001 Boehringer Ingelheim Investigational Site
      • Istanbul, 칠면조
        • 1160.47.90002 Boehringer Ingelheim Investigational Site
      • Istanbul, 칠면조
        • 1160.47.90007 Boehringer Ingelheim Investigational Site
      • Izmir, 칠면조
        • 1160.47.90006 Boehringer Ingelheim Investigational Site
    • Alberta
      • Edmonton, Alberta, 캐나다
        • 1160.47.02006 Boehringer Ingelheim Investigational Site
      • Edmonton, Alberta, 캐나다
        • 1160.47.02013 Boehringer Ingelheim Investigational Site
    • British Columbia
      • Victoria, British Columbia, 캐나다
        • 1160.47.02021 Boehringer Ingelheim Investigational Site
    • New Brunswick
      • Saint Johns, New Brunswick, 캐나다
        • 1160.47.02004 Boehringer Ingelheim Investigational Site
    • Nova Scotia
      • Halifax, Nova Scotia, 캐나다
        • 1160.47.02001 Boehringer Ingelheim Investigational Site
    • Ontario
      • Hamilton, Ontario, 캐나다
        • 1160.47.02002 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, 캐나다
        • 1160.47.02005 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, 캐나다
        • 1160.47.02010 Boehringer Ingelheim Investigational Site
      • Hamilton, Ontario, 캐나다
        • 1160.47.02022 Boehringer Ingelheim Investigational Site
      • Ottawa, Ontario, 캐나다
        • 1160.47.02015 Boehringer Ingelheim Investigational Site
      • Toronto, Ontario, 캐나다
        • 1160.47.02019 Boehringer Ingelheim Investigational Site
    • Quebec
      • Montreal, Quebec, 캐나다
        • 1160.47.02008 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, 캐나다
        • 1160.47.02009 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, 캐나다
        • 1160.47.02014 Boehringer Ingelheim Investigational Site
      • Montreal, Quebec, 캐나다
        • 1160.47.02017 Boehringer Ingelheim Investigational Site
      • Almada, 포르투갈
        • 1160.47.35104 Boehringer Ingelheim Investigational Site
      • Coimbra, 포르투갈
        • 1160.47.35109 Boehringer Ingelheim Investigational Site
      • Covilhã, 포르투갈
        • 1160.47.35107 Boehringer Ingelheim Investigational Site
      • Lisboa, 포르투갈
        • 1160.47.35101 Boehringer Ingelheim Investigational Site
      • Lisboa, 포르투갈
        • 1160.47.35102 Boehringer Ingelheim Investigational Site
      • Lisboa, 포르투갈
        • 1160.47.35105 Boehringer Ingelheim Investigational Site
      • Kielce, 폴란드
        • 1160.47.48004 Boehringer Ingelheim Investigational Site
      • Krakow, 폴란드
        • 1160.47.48005 Boehringer Ingelheim Investigational Site
      • Krakow, 폴란드
        • 1160.47.48007 Boehringer Ingelheim Investigational Site
      • Poznan, 폴란드
        • 1160.47.48003 Boehringer Ingelheim Investigational Site
      • Warsaw, 폴란드
        • 1160.47.48006 Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301A Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301B Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301C Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301D Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301E Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301F Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301H Boehringer Ingelheim Investigational Site
      • Brest Cedex, 프랑스
        • 1160.47.3301I Boehringer Ingelheim Investigational Site
      • Lorient, 프랑스
        • 1160.47.3302A Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, 프랑스
        • 1160.47.3303A Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, 프랑스
        • 1160.47.3303B Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, 프랑스
        • 1160.47.3303C Boehringer Ingelheim Investigational Site
      • St Etienne Cedex 2, 프랑스
        • 1160.47.3303D Boehringer Ingelheim Investigational Site
      • Vandoeuvre les Nancy, 프랑스
        • 1160.47.3308A Boehringer Ingelheim Investigational Site
      • Espoo, 핀란드
        • 1160.47.35804 Boehringer Ingelheim Investigational Site
      • Helsinki, 핀란드
        • 1160.47.35801 Boehringer Ingelheim Investigational Site
      • Jyväskylä, 핀란드
        • 1160.47.35802 Boehringer Ingelheim Investigational Site
      • Kuopio, 핀란드
        • 1160.47.35805 Boehringer Ingelheim Investigational Site
      • Tampere, 핀란드
        • 1160.47.35803 Boehringer Ingelheim Investigational Site
      • Budapest, 헝가리
        • 1160.47.36001 Boehringer Ingelheim Investigational Site
      • Budapest, 헝가리
        • 1160.47.36006 Boehringer Ingelheim Investigational Site
      • Budapest, 헝가리
        • 1160.47.36007 Boehringer Ingelheim Investigational Site
      • Debrecen, 헝가리
        • 1160.47.36002 Boehringer Ingelheim Investigational Site
      • Gyula, 헝가리
        • 1160.47.36012 Boehringer Ingelheim Investigational Site
      • Miskolc, 헝가리
        • 1160.47.36004 Boehringer Ingelheim Investigational Site
      • Pecs, 헝가리
        • 1160.47.36003 Boehringer Ingelheim Investigational Site
      • Szombathely, 헝가리
        • 1160.47.36011 Boehringer Ingelheim Investigational Site
      • Székesfehérvár, 헝가리
        • 1160.47.36010 Boehringer Ingelheim Investigational Site
    • Queensland
      • Wooloongabba, Queensland, 호주
        • 1160.47.61002 Princess Alexandra Hospital
    • South Australia
      • Bedford Park, South Australia, 호주
        • 1160.47.61004 Boehringer Ingelheim Investigational Site
    • Victoria
      • Box Hill, Victoria, 호주
        • 1160.47.61003 Boehringer Ingelheim Investigational Site
      • Clayton, Victoria, 호주
        • 1160.47.61001 Boehringer Ingelheim Investigational Site
      • Windsor, Victoria, 호주
        • 1160.47.61006 Boehringer Ingelheim Investigational Site
    • Western Australia
      • Perth, Western Australia, 호주
        • 1160.47.61005 Boehringer Ingelheim Investigational Site

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion criteria:

Inclusion_Criteria

  • Acute symptomatic deep vein thrombosis (DVT)
  • Pulmonary embolism (PE) 3-12 months prior to screening, which has been documented by objective testing

Exclusion criteria:

Exclusion_Criteria

  • Symptomatic DVT or PE at screening Interruption of anticoagulant therapy for 2 or more weeks during the 3-12 months of treatment for the prior VTE.
  • Patients who in the investigators judgement are perceived as having an excessive risk of bleeding Elevated Aspartate aminotransferase (AST) or Alanine tranminase (ALT) > 2x ULN
  • Severe renal impairment (estimated creatinine clearance <= 30 ml/min)

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 더블

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Dabigatran
Patient to receive 1 capsule containing dabigatran 150 mg twice daily plus placebo tablets for warfarin as decided by sham INR measurements
Dabigatran 150 mg BID (twice daily)
활성 비교기: Warfarin (INR of 2.0-3.0)
Patient to receive warfarin tablets to target INR 2.0-3.0 plus placebo capsules for dabigatran twice daily
Warfarin dosed individually to maintain INR 2.0-3.0

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Composite of Recurrent VTE or VTE Death at 36 Months
기간: 36 months
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.
36 months
Composite of Recurrent VTE or VTE Death at 18 Months
기간: 18 months
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and death related to VTE. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation. In case of death, autopsy was an additional way to confirm VTE.
18 months

2차 결과 측정

결과 측정
측정값 설명
기간
Composite of Recurrent VTE or All Cause Death at 36 Months
기간: 36 months
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.
36 months
Composite of Recurrent VTE or All Cause Death at 18 Months
기간: 18 months
Endpoint is a composite of recurrent Venous Thromboembolic Event (VTE) and all cause death. VTE was defined as the composite of symptomatic Deep Vein Thrombosis (DVT) of the leg and Pulmonary embolism (PE). All recurrent VTEs required objective verification by definitive diagnostic evaluation.
18 months
Deep Vein Thrombosis (DVT) at 36 Months
기간: 36 months
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.
36 months
DVT at 18 Months
기간: 18 months
Symptomatic Deep vein thrombosis (DVT). All DVT events required objective verification through definitive diagnostic evaluation.
18 months
Symptomatic Pulmonary Embolism (PE) at 36 Months
기간: 36 months
Symptomatic pulmonary embolism (PE) at 36 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.
36 months
Symptomatic Pulmonary Embolism (PE) at 18 Months
기간: 18 months
Symptomatic pulmonary embolism (PE) at 18 Months (fatal or non-fatal). All suspected PEs required confirmation by one of the following: ventilation-perfusion (V-Q) lung scan, pulmonary angiography, or spiral (helical) Computed tomography.
18 months
Deaths Related to VTE at 36 Months
기간: 36 months
Deaths related to VTE (i.e. fatal PE) at 36 Months. Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.
36 months
Deaths Related to VTE at 18 Months
기간: 18 months
Deaths related to VTE (i.e. fatal PE) at 18 Months. All deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death in a treatment-blinded way.
18 months
Deaths of All Causes at 36 Months
기간: 36 months
Deaths of all causes at 36 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.
36 months
Deaths of All Causes at 18 Months
기간: 18 months
Deaths of all causes at 18 Months. All components of the primary efficacy endpoint and all deaths were centrally adjudicated by the Independent Central Adjudication Committee for VTE and death without knowledge of any individual treatment assignments.
18 months
Number of Participants With Bleeding Events
기간: first intake of study drug until 6 days following last intake of study drug

MBE (major bleeding event) if it fulfilled at least one of the following criteria

  • Fatal bleeding
  • Symptomatic bleeding in a critical area or organ.
  • Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) or more, or leading to transfusion of 2 or more units of whole blood or red cells.

Minor bleeding event was any bleeding that did not fulfil any of the criteria for MBEs

CRBE (clinically relevant bleeding event) if it is a minor bleeding events which fulfilled at least one of the following criteria

  • Spontaneous skin haematoma ≥25 cm2
  • Spontaneous nose bleed >5 min duration
  • Macroscopic haematuria, either spontaneous or, if associated with an intervention, lasting >24 h
  • Spontaneous rectal bleeding
  • Gingival bleeding >5 min
  • Bleeding leading to hospitalisation or requiring surgical treatment
  • Bleeding leading to a transfusion of <2 units of whole blood or red cells
  • Any other bleeding event considered clinically relevant by the investigator
first intake of study drug until 6 days following last intake of study drug
Laboratory Analysis
기간: 18 months + 30 days follow up
Patients with LFT (liver function tests) increases of possible clinical significance during treatment. Increases of possible clinical significance were defined as: ≥3 x ULN (AST, ALT), ≥2 x ULN (AP), and ≥2 mg/dL (total bilirubin). Only patients with a baseline value which was not of possible clinical significance (or without any baseline value) could have a PCSA (Possible clinically significant abnormality).
18 months + 30 days follow up
Number of Participants With Definite Acute Coronary Syndrome (ACS)
기간: day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination
All suspected ACS occurring during the trial were to be recorded on the CRF and were to be centrally adjudicated by an independent ACS/AC in a treatment-blinded manner.
day of first study drug intake until last day of study drug intake; from the day after last intake of study drug until trial termination

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

유용한 링크

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작

2006년 5월 1일

기본 완료 (실제)

2010년 10월 1일

연구 등록 날짜

최초 제출

2006년 5월 23일

QC 기준을 충족하는 최초 제출

2006년 5월 23일

처음 게시됨 (추정)

2006년 5월 24일

연구 기록 업데이트

마지막 업데이트 게시됨 (추정)

2014년 5월 19일

QC 기준을 충족하는 마지막 업데이트 제출

2014년 5월 8일

마지막으로 확인됨

2013년 12월 1일

추가 정보

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .

구독하다